These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29791021)

  • 1. ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.
    Zhang H; Li Y; Liu X; Liang Z; Yan M; Liu Q; Chen A; Bao Y; Zhou C; Li S; Yee C; Li Y
    Immunology; 2018 Oct; 155(2):238-250. PubMed ID: 29791021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
    Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
    Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
    John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
    Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
    Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
    Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of allograft rejection by CD8+CD122+PD-1+ Tregs is dictated by their Fas ligand-initiated killing of effector T cells versus Fas-mediated own apoptosis.
    Liu H; Wang Y; Zeng Q; Zeng YQ; Liang CL; Qiu F; Nie H; Dai Z
    Oncotarget; 2017 Apr; 8(15):24187-24195. PubMed ID: 28445940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells.
    Akiyama Y; Nonomura C; Kondou R; Miyata H; Ashizawa T; Maeda C; Mitsuya K; Hayashi N; Nakasu Y; Yamaguchi K
    Int J Oncol; 2016 Sep; 49(3):1099-107. PubMed ID: 27573705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
    Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM
    J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolic acid-treated dendritic cells generate regulatory CD4+ T cells that suppress CD8+ T cells' allocytotoxicity.
    Kazma I; Lemoine R; Herr F; Chadet S; Meley D; Velge-Roussel F; Lebranchu Y; Baron C
    Int Immunol; 2014 Mar; 26(3):173-81. PubMed ID: 24222014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
    Toor SM; Syed Khaja AS; Alkurd I; Elkord E
    Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ImmTACs for targeted cancer therapy: Why, what, how, and which.
    Oates J; Hassan NJ; Jakobsen BK
    Mol Immunol; 2015 Oct; 67(2 Pt A):67-74. PubMed ID: 25708206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.
    Shindo Y; Unsinger J; Burnham CA; Green JM; Hotchkiss RS
    Shock; 2015 Apr; 43(4):334-43. PubMed ID: 25565644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.
    Huss DJ; Pellerin AF; Collette BP; Kannan AK; Peng L; Datta A; Wipke BT; Fontenot JD
    Immunology; 2016 Jul; 148(3):276-86. PubMed ID: 27012310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.